SLXN NASDAQ
Jerusalem, TA 9112001
IL
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Shirvan Mitchell | A-Award | 6,000 | — | 2026-06-04 |
| Horenshtein Hadar Mi | A-Award | 7,500 | — | 2026-06-04 |
| Hadar Ilan | A-Award | 10,000 | — | 2026-06-04 |
| Shirvan Mitchell | S-Sale | 22,818 | $1.36 | 2026-03-26 |
| Noy Shlomo | A-Award | 9,091 | — | 2026-02-20 |